Therefore, in this study, our objective is to compare the efficacy and safety of triple therapy and TKI plus PD-1 inhibitors (dual therapy) in first-line treatment for patients with high-risk aHCC, defined as Vp4 or/and tumor diameter ≥10 cm. Here, PDCD1 is linked to neoplasm.